CTOs on the Move

TransCode Therapeutics

www.transcodetherapeutics.com

 
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Zdravka Medarova
 Chief Technology Officer Profile

Similar Companies

Strategic BH Raleigh

Strategic Behavioral Health is a national mental health facility offering inpatient & outpatient treatment programs. We help families put their lives back together.

Aphena Pharma Solutions New Jersey

Aphena Pharma Solutions New Jersey is a Whippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vista del Mar

Vista del Mar Hospital offers adolescent & adult inpatient psychiatric care, adult detox/dual diagnosis and partial hospitalization programs.

GL Sciences

GL Sciences is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diamedica

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.